Paliperidone palmitate-induced facial angioedema: A case report

© 2020 Elsevier Ltd BACKGROUND: Paliperidone palmitate is a once-monthly injectable, atypical antipsychotic. To our knowledge, there has been only one report of paliperidone palmitate-induced angioedema presenting with acute laryngeal edema with subsequent respiratory arrest. Here, we present a case...

Full description

Saved in:
Bibliographic Details
Main Authors: Maytinee Srifuengfung, Thanisorn Sukakul, Chanika Liangcheep, Natee Viravan
Other Authors: Faculty of Medicine, Siriraj Hospital, Mahidol University
Format: Article
Published: 2020
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/60038
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University
id th-mahidol.60038
record_format dspace
spelling th-mahidol.600382020-11-18T16:57:42Z Paliperidone palmitate-induced facial angioedema: A case report Maytinee Srifuengfung Thanisorn Sukakul Chanika Liangcheep Natee Viravan Faculty of Medicine, Siriraj Hospital, Mahidol University Medicine © 2020 Elsevier Ltd BACKGROUND: Paliperidone palmitate is a once-monthly injectable, atypical antipsychotic. To our knowledge, there has been only one report of paliperidone palmitate-induced angioedema presenting with acute laryngeal edema with subsequent respiratory arrest. Here, we present a case report of paliperidone palmitate-induced angioedema with a relatively mild clinical presentation compared with the previously reported case, and the patient's condition was not complicated by life-threatening anaphylaxis. CASE SUMMARY: A 79-year-old female, who had a major neurocognitive disorder due to Alzheimer's disease with behavioral disturbances. Paliperidone palmitate was off- label used to control her aggression, irritability, and psychosis. After induction doses (150 mg and 100 mg intramuscularly, given 1 wk apart), she developed intermittent swelling of the face, eyelids, and lips on day 17 after the initial dose, and the edema was explicitly seen on day 20. The diagnosis was paliperidone palmitate-induced angioedema. The monthly injection dose was discontinued on day 33 after the initial dose. The angioedema was subsequently alleviated, and it had completely resolved by day 40 after the initial dose. CONCLUSION: Paliperidone palmitate-induced angioedema is a rare condition and can present with a mild, intermittent facial edema, which may be overlooked in clinical practice. 2020-11-18T09:57:42Z 2020-11-18T09:57:42Z 2020-10-26 Article World Journal of Clinical Cases. Vol.8, No.20 (2020), 4876-4882 10.12998/wjcc.v8.i20.4876 23078960 2-s2.0-85095768571 https://repository.li.mahidol.ac.th/handle/123456789/60038 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85095768571&origin=inward
institution Mahidol University
building Mahidol University Library
continent Asia
country Thailand
Thailand
content_provider Mahidol University Library
collection Mahidol University Institutional Repository
topic Medicine
spellingShingle Medicine
Maytinee Srifuengfung
Thanisorn Sukakul
Chanika Liangcheep
Natee Viravan
Paliperidone palmitate-induced facial angioedema: A case report
description © 2020 Elsevier Ltd BACKGROUND: Paliperidone palmitate is a once-monthly injectable, atypical antipsychotic. To our knowledge, there has been only one report of paliperidone palmitate-induced angioedema presenting with acute laryngeal edema with subsequent respiratory arrest. Here, we present a case report of paliperidone palmitate-induced angioedema with a relatively mild clinical presentation compared with the previously reported case, and the patient's condition was not complicated by life-threatening anaphylaxis. CASE SUMMARY: A 79-year-old female, who had a major neurocognitive disorder due to Alzheimer's disease with behavioral disturbances. Paliperidone palmitate was off- label used to control her aggression, irritability, and psychosis. After induction doses (150 mg and 100 mg intramuscularly, given 1 wk apart), she developed intermittent swelling of the face, eyelids, and lips on day 17 after the initial dose, and the edema was explicitly seen on day 20. The diagnosis was paliperidone palmitate-induced angioedema. The monthly injection dose was discontinued on day 33 after the initial dose. The angioedema was subsequently alleviated, and it had completely resolved by day 40 after the initial dose. CONCLUSION: Paliperidone palmitate-induced angioedema is a rare condition and can present with a mild, intermittent facial edema, which may be overlooked in clinical practice.
author2 Faculty of Medicine, Siriraj Hospital, Mahidol University
author_facet Faculty of Medicine, Siriraj Hospital, Mahidol University
Maytinee Srifuengfung
Thanisorn Sukakul
Chanika Liangcheep
Natee Viravan
format Article
author Maytinee Srifuengfung
Thanisorn Sukakul
Chanika Liangcheep
Natee Viravan
author_sort Maytinee Srifuengfung
title Paliperidone palmitate-induced facial angioedema: A case report
title_short Paliperidone palmitate-induced facial angioedema: A case report
title_full Paliperidone palmitate-induced facial angioedema: A case report
title_fullStr Paliperidone palmitate-induced facial angioedema: A case report
title_full_unstemmed Paliperidone palmitate-induced facial angioedema: A case report
title_sort paliperidone palmitate-induced facial angioedema: a case report
publishDate 2020
url https://repository.li.mahidol.ac.th/handle/123456789/60038
_version_ 1763487250034720768